Shandong Realcan Pharmaceutical Co Ltd (002589) - Total Assets
Based on the latest financial reports, Shandong Realcan Pharmaceutical Co Ltd (002589) holds total assets worth CN¥15.55 Billion CNY (≈ $2.27 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Shandong Realcan Pharmaceutical Co Ltd cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Shandong Realcan Pharmaceutical Co Ltd - Total Assets Trend (2008–2025)
This chart illustrates how Shandong Realcan Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Shandong Realcan Pharmaceutical Co Ltd for net asset value and shareholders' equity analysis.
Shandong Realcan Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Shandong Realcan Pharmaceutical Co Ltd's total assets of CN¥15.55 Billion consist of 65.8% current assets and 34.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 26.1% |
| Accounts Receivable | CN¥3.71 Billion | 25.8% |
| Inventory | CN¥715.30 Million | 5.0% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥528.80 Million | 3.7% |
| Goodwill | CN¥146.67 Million | 1.0% |
Asset Composition Trend (2008–2025)
This chart illustrates how Shandong Realcan Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 002589 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shandong Realcan Pharmaceutical Co Ltd's current assets represent 65.8% of total assets in 2025, a decrease from 92.2% in 2008.
- Cash Position: Cash and equivalents constituted 26.1% of total assets in 2025, up from 11.2% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 1.0% in 2008.
- Asset Diversification: The largest asset category is accounts receivable at 25.8% of total assets.
Shandong Realcan Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Shandong Realcan Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
China National Medicines Corp Ltd
SHG:600511
|
China | CN¥35.13 Billion |
|
AKSO HEALTH GR. (SPADR)/3
F:8HX
|
Germany | €212.04 Million |
|
China National Accord Medicines Corp Ltd
SHE:200028
|
China | HK$49.12 Billion |
|
Cyclopharm Ltd
AU:CYC
|
Australia | AU$46.10 Million |
|
Sigma Healthcare Ltd
AU:SIG
|
Australia | AU$8.74 Billion |
|
Ebos Group Ltd
AU:EBO
|
Australia | AU$8.80 Billion |
|
Paragon Care Ltd
AU:PGC
|
Australia | AU$1.31 Billion |
|
Mayne Pharma Group Ltd
AU:MYX
|
Australia | AU$1.01 Billion |
Shandong Realcan Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.10 | 1.12 | 1.24 |
| Quick Ratio | 1.03 | 1.05 | 1.11 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥948.80 Million | CN¥1.22 Billion | CN¥4.61 Billion |
Shandong Realcan Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shandong Realcan Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.75 |
| Latest Market Cap to Assets Ratio | 0.04 |
| Asset Growth Rate (YoY) | -10.3% |
| Total Assets | CN¥14.37 Billion |
| Market Capitalization | $592.30 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shandong Realcan Pharmaceutical Co Ltd's assets below their book value (0.04x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Shandong Realcan Pharmaceutical Co Ltd's assets decreased by 10.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shandong Realcan Pharmaceutical Co Ltd (2008–2025)
The table below shows the annual total assets of Shandong Realcan Pharmaceutical Co Ltd from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥14.37 Billion ≈ $2.10 Billion |
-10.26% |
| 2024-12-31 | CN¥16.01 Billion ≈ $2.34 Billion |
-4.17% |
| 2023-12-31 | CN¥16.71 Billion ≈ $2.45 Billion |
-8.85% |
| 2022-12-31 | CN¥18.33 Billion ≈ $2.68 Billion |
-30.56% |
| 2021-12-31 | CN¥26.40 Billion ≈ $3.86 Billion |
-15.64% |
| 2020-12-31 | CN¥31.29 Billion ≈ $4.58 Billion |
-3.62% |
| 2019-12-31 | CN¥32.47 Billion ≈ $4.75 Billion |
-6.81% |
| 2018-12-31 | CN¥34.84 Billion ≈ $5.10 Billion |
+29.10% |
| 2017-12-31 | CN¥26.98 Billion ≈ $3.95 Billion |
+72.34% |
| 2016-12-31 | CN¥15.66 Billion ≈ $2.29 Billion |
+76.68% |
| 2015-12-31 | CN¥8.86 Billion ≈ $1.30 Billion |
+56.06% |
| 2014-12-31 | CN¥5.68 Billion ≈ $830.92 Million |
+27.48% |
| 2013-12-31 | CN¥4.45 Billion ≈ $651.79 Million |
+42.75% |
| 2012-12-31 | CN¥3.12 Billion ≈ $456.61 Million |
+40.71% |
| 2011-12-31 | CN¥2.22 Billion ≈ $324.50 Million |
+49.89% |
| 2010-12-31 | CN¥1.48 Billion ≈ $216.49 Million |
+42.26% |
| 2009-12-31 | CN¥1.04 Billion ≈ $152.18 Million |
+45.34% |
| 2008-12-31 | CN¥715.53 Million ≈ $104.70 Million |
-- |
About Shandong Realcan Pharmaceutical Co Ltd
Realcan Pharmaceutical Group Co., Ltd. sells medicines, medical devices, and medical consumables to medical institutions in China. It operates through the Drug and Equipment Distribution, In Vitro Diagnostics, Pharmaceutical Logistics, Traditional Chinese Medicine, and Microbiome Medicine segments. The company engages in the processing, manufacture, sale, and wholesale of Chinese medicinal materi… Read more